Investor Presentation

November 05, 2026 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam, Subject : Investor Presentation on Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and six months ended September 30, 2026 Stock Code : BSE – 539787, NSE – HCG Reference : Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) This is to inform you that the Board of Directors of the Company, at their meeting held today i.e., November 05, 2026, inter alia, has considered and approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and six months ended September 30, 2026 (“Unaudited Financial Results”). We enclose herewith the Investor Presentation on the Unaudited Financial Results of the Company. The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/investor-relations/ You are requested to take the intimation on record. Thanking you, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary & Compliance Officer Encl: a/a HealthCare Global Enterprises Limited Reg Off: HCG Towers #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027 Corp Off: #3, G-Floor, Tower Block, Unity Buildings Complex, Mission Road, Bengaluru - 560 027, Karnataka, India 91 80 4660 7700 | Emall-query@hcgel.com | Website - www.hcgoncology.com | CIN: L15200KA1998PLC023489 Ahmedabad | Bengaluru | Bhavnagar | Chennai | Cuttack | Hubballi | Indore | Jaipur | Kalaburagi | Kenya | Kolkata | Mumbai | Nagpur | Nashik | Ongole | Rajkot | Ranchi | Shimoga | Vadodara | Vijayawada | Vizag HEALTHCARE GLOBAL ENTERPRISES LIMITED Q2 and H1 FY2027 Results Presentation November 5, 2026 Safe Harbor This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This presentation has been prepared by HealthCare Global Enterprises Limited (the "Company"). These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States. The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction. No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point. This presentation contains certain "forward looking statements". Forward‐looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward‐looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof. This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm. wwww.hcgoncologwy.com w.hcgoncology.com Q2 FY27: Performance Update Q2 FY27: Performance Update Revenue grew 16% YoY, while Adjusted EBITDA grew 17% YoY, with margins of 19.7% in Q2 FY27 Financial Highlights 7,318 Mn 1,425 Mn 1,364 Mn 301 Mn 192 Mn Revenue Adjusted EBITDA1 Operational EBITDA2 Profit before Tax3 Adjusted PAT4 Margins Margins 48% Margins -9% Margins 16% y-o-y 17% y-o-y 19.7% 12% y-o-y 18.6% y-o-y 4.1% y-o-y 2.6% Operational Highlights 82,405 88,805 69% 2,880 Volume ARPP Non-Institutional Mix Operational Beds 146 Beds 9% y-o-y 7% y-o-y 325 bps y-o-y Addition H1FY27 Notes: 1. Adjusted EBITDA excludes North Bangalore Loss (INR 61 Mn) and ESOP expenses (INR 30 Mn). The Adjusted EBITDA margin is calculated on revenue excluding North Bangalore revenue of INR 99 Mn in Q2 FY27 2. Operational EBITDA is excluding ESOP expenses 3. PBT is before extraordinary item of INR 116 Mn in Q2 FY27 4. Adjusted PAT normalized for extraordinary item (net of tax) in Q2 FY27. The YoY decline primarily reflects a favourable one-time deferred tax adjustment in Q2 FY26 against brought-forward losses and unabsorbed depreciation at Baroda 5. All the above figures exclude the fertility business, following its divestment effective 30 June 2026 wwww.hcgoncologwy.com w.hcgoncology.com HCG Key Highlights: Q2 FY27 HCG Key Highlights: Q2 FY27 HCG delivered revenue of INR 7,318 Mn in Q2FY27, reflecting ~16% YoY growth • Broad-based growth continued across clusters in Q2FY27. Revenue growth was led by volume growth of 9% YoY. ARPP grew by 7%, improvement driven by a favourable payor mix and increased contribution from high-end therapies, including robotic s [Showing first 8,000 characters — download PDF for full document]